6-bromo-5-methoxybenzo[d]thiazol-2-amine | 1092120-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 6-bromo-5-methoxybenzo[d]thiazol-2-amine
• 英文别名: 6-Bromo-5-methoxy-1,3-benzothiazol-2-amine；6-bromo-5-methoxy-1,3-benzothiazol-2-amine
• CAS: 1092120-21-2
• 化学式: C₈H₇BrN₂OS
• 分子量: 259.126
• InChiKey: NNHNIBUSODSJMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  76.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-5-methoxybenzo[d]thiazol-2-amine 在 叔丁基硝酸酯 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 2.0h， 以24%的产率得到6-bromo-5-methoxy-1,3-benzothiazole
  参考文献：
  名称：

  [EN] 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES
  [FR] COMPOSÉS DE 5- ET 6-AZAINDOLE POUR L'INHIBITION DE TYROSINE KINASES BCR-ABL

  摘要：

  本公开涉及抑制Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如慢性髓细胞白血病（CML）中的应用。

  公开号：

  WO2022076975A1
• 作为产物：
  描述：

  4-溴-3-甲氧基苯胺 在 水 、 溴 、 sodium hydroxide 作用下， 以 甲醇 、 溶剂黄146 、 丙酮 为溶剂， 反应 3.0h， 生成 6-bromo-5-methoxybenzo[d]thiazol-2-amine
  参考文献：
  名称：

  ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON VASCULAR ENDOTHELIAL LIPASE

  摘要：

  公开号：

  EP2351744B1

文献信息

• (3R)-3-Amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
  作者：Aiko Nitta、Hideaki Fujii、Satoshi Sakami、Yutaka Nishimura、Tomofumi Ohyama、Mikiya Satoh、Junko Nakaki、Shiho Satoh、Chifumi Inada、Hideki Kozono、Hiroki Kumagai、Masahiro Shimamura、Tominaga Fukazawa、Hideki Kawai

  DOI：10.1016/j.bmcl.2008.09.042

  日期：2008.10

  and 3-amino-N-(4-aryltetrahydropyran-4-yl)butanamides were synthesized and evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors. Derivatives incorporating the 6-substituted benzothiazole group showed highly potent DPP-IV inhibitory activity. Oral administration of (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-4-[6-(2-methoxyethoxy)benzothiazol-2-yl ]tetrahydropyran-4-yl}butanamide (12u) reduced blood

  合成了一系列新颖的3-氨基-N-（4-芳基-1,1-二氧噻吩-4-基）丁酰胺和3-氨基-N-（4-芳基四氢吡喃-4-基）丁酰胺并评估为二肽基肽酶IV （DPP-IV）抑制剂。掺入6-取代的苯并噻唑基团的衍生物显示出强效的DPP-IV抑制活性。（3R）-3-氨基-4-（2,4,5-三氟苯基）-N- 4- [6-（2-甲氧基乙氧基）苯并噻唑-2-基]四氢吡喃-4-基}丁酰胺的口服给药（ 12u）在口服葡萄糖耐量试验中降低了血糖偏移。
• [EN] 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES<br/>[FR] COMPOSÉS DE 5- ET 6-AZAINDOLE POUR L'INHIBITION DE TYROSINE KINASES BCR-ABL
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022076975A1

  公开（公告）日：2022-04-14

  The present disclosure relates to compounds and compositions for inhibition of Bcr- Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

  本公开涉及抑制Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如慢性髓细胞白血病（CML）中的应用。
• ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE
  申请人：Masuda Koji

  公开号：US20110251386A1

  公开（公告）日：2011-10-13

  Disclosed is a compound which is useful as an endothelial lipase inhibitor. A pharmaceutical composition having inhibitory activity on endothelial lipase comprising a compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is nitrogen-containing hetero ring, Ring A may be substituted with a substituent other than a group represented by the formula: —C(R 1 R 2 )—C(═O)—NR 3 R 4 and a group represented by the formula: —R 5 , a broken line represents the presence or the absence of a bond, Z is —NR 6 —, ═N—, —O—, or —S—, R 6 is halogen, substituted or unsubstituted alkyl or the like, R 1 and R 2 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy or substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is hydrogen, substituted or unsubstituted alkyl or the like, R 3 and R 4 taken together with the adjacent nitrogen atom to which they are attached may form a substituted or unsubstituted ring, R 5 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like.

  公开了一种作为内皮酯酶抑制剂有用的化合物。一种具有内皮酯酶抑制活性的药物组合物，包括下式所示的化合物：其药学上可接受的盐或其溶剂合物，其中，环A是含氮杂环，环A可以被除了由下式表示的基团：—C(R1R2)—C(═O)—NR3R4和由下式表示的基团：—R5以外的基团取代，其中，一条虚线表示键的存在或不存在，Z为—NR6—，═N—，—O—或—S—，R6为卤素，取代或未取代的烷基或类似物，R1和R2各自独立地为氢、卤素、羟基、氰基、硝基、羧基或取代或未取代的烷基，R3为氢或取代或未取代的烷基，R4为氢、取代或未取代的烷基或类似物，R3和R4与它们所连接的相邻氮原子一起可以形成取代或未取代的环，R5为氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基或类似物。
• Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant
  作者：Seunghee Hong、Jinhee Kim、Sun-Mi Yun、Hyunseung Lee、Yoonsu Park、Soon-Sun Hong、Sungwoo Hong

  DOI：10.1021/jm301891t

  日期：2013.5.9

  The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.
• US8957219B2
  申请人：——

  公开号：US8957219B2

  公开（公告）日：2015-02-17